Ignite Creation Date:
2025-12-24 @ 7:16 PM
Ignite Modification Date:
2025-12-27 @ 6:18 PM
Study NCT ID:
NCT05268003
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-05
First Post:
2022-02-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2026-10-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10-05
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-17
First Submit QC Date:
None
Study First Post Date:
2022-03-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-04
Last Update Post Date:
2025-09-05
Last Update Post Date Type:
ESTIMATED